A Phase 1/2 interventional study of PF-07868489 and Placebo for PF-07868489 in Pulmonary Arterial Hypertension, sponsored by Pfizer. Completed at 46 sites in 12 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Pfizer · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pulmonary Arterial Hypertension by Pfizer — none open to participants now, none under way, none of them phase 3. Pulmonary Arterial Hypertension · Pfizer.
Among the 11 studies in Pulmonary Arterial Hypertension by Pfizer, this one is the only one that started in 2023, is the only one in phase 1/2, and was the 11th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 11 studies in Pulmonary Arterial Hypertension by Pfizer is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 57 across the 8 interventional studies, 54 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Pulmonary Arterial Hypertension by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH).
Part A:
An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants.
Part B:
A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.
Key Inclusion Criteria Part A:
Key Exclusion Criteria Part A:
Key Inclusion Criteria Part B:
Key Exclusion Criteria Part B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
Drug: PF-07868489
single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
Drug: Placebo for PF-07868489
Experimental Treatment
Placebo
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Part A
Time frame: Baseline up to Day 113.
Number of Participants With Change From Baseline in Laboratory Tests Results
Part A
Time frame: Baseline up to Day 113
Number of Participants With Vital Sign Abnormalities
Part A
Time frame: Baseline up to Day 113
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
Part A
Time frame: Baseline up to Day 113
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Part B
Time frame: Baseline up to Day 253
Number of Participants With Change From Baseline in Laboratory Tests Results
Part B
Time frame: Baseline up to Day 253
Number of Participants With Vital Sign Abnormalities
Part B
Time frame: Baseline up to Day 253
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
Part B
Time frame: Baseline up to Day 253
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week24
repeated doses
Time frame: Baseline, Week 24
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast)
single dose
Time frame: Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
single dose
Time frame: Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose
Maximum Observed Plasma Concentration (Cmax)
single dose
Time frame: Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
single dose
Time frame: 4-7 days
Incidence of Anti-Drug Antibody (ADA)
single dose
Time frame: Baseline and up to week 16
Plasma Decay Half-Life (t1/2)
single dose
Time frame: Day 113
Minimum Observed Plasma Trough Concentration (Cmin)
repeat doses
Time frame: Day 253
Plasma Decay Half-Life (t1/2)
repeat doses
Time frame: Day 253
Incidence of Anti-Drug Antibody (ADA)
repeated doses
Time frame: Baseline and up to Day 253
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week24
repeated doses
Time frame: Baseline, Week 24
6MWD
repeated doses
Time frame: Baseline, Week 24
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2023 to primary completion in Jul 2026, 32 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →